Regulations.gov document
Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research…
Notice · FDA-2020-D-1079 · posted Jul 22, 2020
Key facts
| Document ID | FDA-2020-D-1079-0001 |
|---|---|
| Title | Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research; Draft Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2020-D-1079 |
| Posted | Jul 22, 2020 |
| Federal Register citation | 85 FR 44305 |
| FR document number | 2020-15907 |
| Comment period opens | Jul 22, 2020 |
| Comments due | Sep 22, 2020 |
| Effective date | Jul 22, 2020 |
At a glance
- 1–9 Pages
- No Open for comment
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: